Google
NVAX 株価分析 — Novavax Inc (Healthcare >> Biotechnology)
NVAX に関するよくある質問
NVAXのPER（株価収益率）は？
Novavax Inc（NVAX）は現在PER 9.82倍で取引されています。
NVAXのROE（自己資本利益率）は？
Novavax IncのROEは60.68%です。
NVAXの配当利回りは？
Novavax Incの配当利回りは0.00%です。
NVAXの品質スコア（Quality Score）は？
当社のAIはNVAXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NVAXは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NVAXはどのセクターに属しますか？
Novavax IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
NVAX AI Analysis Summary
Our AI summary for NVAX: Novavax Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 9.82, ROE of 60.68%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.66
Price
0.25
(3.37%)
Day Change
|
|
|---|
NVAX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
135
|
| Magic Formula Rank by ROE |
135
|
| Magic Formula Rank by ROIC |
149
|
| Price | 7.66 |
| PBV / Sector |
-8.42 / 44,022.72
|
| Earning Per Share | -0.55 |
| PE / Sector |
9.82 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
-0.07 / 1.24
|
| Average 1M Daily Value |
24.25 M
GREAT
|
| Average 1W Daily Value |
21.04 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:37 |
| Symbol | NVAX |
| Name | NOVAVAX INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 164.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,218.49 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 21 Firstfield Road, Gaithersburg, MD, United States, 20878
Phone: 240 268 2000
Website: https://www.novavax.com
Employees: 749
Sector: Healthcare >> Biotechnology
Description: Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
